MediPharm’s Board has issued a detailed letter to shareholders in response to Apollo’s misleading campaign and inadequate plan to take control of your Company with just 3% ownership. Learn why the Board is urging shareholders to vote the GREEN proxy and reject Apollo’s high-risk slate.
CLICK HERE TO READ THE FULL LETTER TO SHAREHOLDERS
The MediPharm Labs Annual and Special Meeting of Shareholders will be held virtually on June 16, 2025, at 3:00 p.m. (Toronto time). Shareholders may attend the live webcast by visiting:
https://meetings.lumiconnect.com/400-049-352-025
Password: medipharm2025 (case sensitive)
During the course of its proxy contest with MediPharm Labs Inc., dissident shareholder Apollo Technology Capital Corp. and its principal, Regan McGee, have made numerous statements that are false or misleading. We provide correct information here for a selection of these misrepresentations.
Under the leadership of your current Board and management, we’ve executed a focused turnaround strategy that is already delivering results—growing revenue, expanding international markets, and improving profitability. Now, a self-interested dissident group—led by an individual with a track record of litigation, failed business ventures, and no public company or sector experience—is trying to seize control of your Company with just a 3% stake and no plan. They offer no strategy, no vision, and no premium to shareholders.
The facts speak for themselves. Learn more about the meaningful progress we’ve made and the focused plan we’re executing to deliver long-term value for all shareholders.
MediPharm’s director nominees offer the right mix of experience, independence, and integrity to protect shareholder value and sustain the Company’s positive momentum. Under the current Board, MediPharm has improved financial results, completed a successful turnaround, and expanded global growth through the acquisition of VIVO Cannabis.
This is not the time to hand control to an unproven dissident group with no credible plan. Support the Board that’s delivering results.
Given the number of issues raised and to debunk the misleading accusations made by Apollo, MediPharm has published detailed information on executive compensation, including independent oversight, pay reductions, and strong alignment with shareholder returns.
Click here for full details on how compensation is set, what directors earn, and why Apollo’s claims don’t hold up.
Send us your questions, comments, and/or feedback and we will get back to you as soon as we can.
